{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:16Z","timestamp":1792801636469,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jconrel.2021.04.030","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T01:48:25Z","timestamp":1619401705000},"page":"237-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects"],"prefix":"10.1016","volume":"334","author":[{"given":"Taslim A.","family":"Al-Hilal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Anwar","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alobaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nozik-Grayck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt R.","family":"Stenmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda A.","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhrul","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.04.030_bb0005","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.29846","article-title":"Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions","volume":"5","author":"Julian","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cm.20472","article-title":"Rho-kinase\/ROCK: a key regulator of the cytoskeleton and cell polarity","volume":"67","author":"Amano","year":"2010","journal-title":"Cytoskeleton (Hoboken)"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","article-title":"ROCK-I and ROCK-II, two isoforms of rho-associated coiled-coil forming protein serine\/threonine kinase in mice","volume":"392","author":"Nakagawa","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.273.5272.245","article-title":"Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)","volume":"273","author":"Kimura","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00109-007-0165-6","article-title":"LIM kinases: function, regulation and association with human disease","volume":"85","author":"Scott","year":"2007","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0030","doi-asserted-by":"crossref","first-page":"24266","DOI":"10.1074\/jbc.273.37.24266","article-title":"Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase","volume":"273","author":"Laufs","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0035","doi-asserted-by":"crossref","first-page":"31725","DOI":"10.1074\/jbc.272.50.31725","article-title":"Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase","volume":"272","author":"Laufs","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0040","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/acs.jmedchem.5b00683","article-title":"Rho kinase (ROCK) inhibitors and their therapeutic potential","volume":"59","author":"Feng","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0045","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1253\/circj.CJ-13-0443","article-title":"Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension","volume":"77","author":"Fukumoto","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FJC.0b013e318070d1bd","article-title":"Rho kinase (ROCK) inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/13543784.2013.778242","article-title":"Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?","volume":"22","author":"Chen","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/TCRM.S2907","article-title":"The therapeutic effects of Rho-ROCK inhibitors on CNS disorders","volume":"4","author":"Kubo","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/14728222.2012.671811","article-title":"Targeting RhoA\/ROCK pathway in pulmonary arterial hypertension","volume":"16","author":"Antoniu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2017.08.002","article-title":"Effects of fasudil on pulmonary hypertension in clinical practice","volume":"46","author":"Zhang","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0075","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.bjp.0707484","article-title":"Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase","volume":"152","author":"Kast","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0080","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1016\/j.bmcl.2014.09.002","article-title":"Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension","volume":"24","author":"Shaw","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0085","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","article-title":"Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys","volume":"48","author":"Tokushige","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0090","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/ICO.0b013e318285475d","article-title":"Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy","volume":"32","author":"Koizumi","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0095","first-page":"883","article-title":"An emerging treatment option for glaucoma: Rho kinase inhibitors","volume":"8","author":"Wang","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0100","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","article-title":"Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers","volume":"126","author":"Tanihara","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2013.01.011","article-title":"Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension","volume":"167","author":"Gupta","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/1074248418772814","article-title":"Inhaled fasudil lacks pulmonary selectivity in thromboxane-induced acute pulmonary hypertension in newborn lambs","volume":"23","author":"Hanson","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v27.i4.20","article-title":"Inhalational therapy for pulmonary arterial hypertension: current status and future prospects","volume":"27","author":"Gupta","year":"2010","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0130","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1158\/1078-0432.CCR-16-0895","article-title":"Molecular pathways: hypoxia-activated prodrugs in cancer therapy","volume":"23","author":"Baran","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0140","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nprot.2016.034","article-title":"Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs","volume":"11","author":"O\u2019Connor","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0150","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/jm00182a027","article-title":"Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents","volume":"23","author":"Teicher","year":"1980","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0155","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1021\/jm00113a040","article-title":"Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells","volume":"34","author":"Firestone","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00689806","article-title":"Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)","volume":"12","author":"Denny","year":"1993","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0165","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-11-0634","article-title":"Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302","volume":"11","author":"Meng","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0170","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","article-title":"Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104","volume":"13","author":"Patterson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0175","first-page":"S429","article-title":"A phase 2 study of TH-4000 in patients with EGFR mutant, T790M-negative, advanced NSCLC progressing on an EGFR TKI","volume":"10","author":"Liu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0180","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/cb4001537","article-title":"CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia\/reoxygenation through inhibition of Chk1 and Aurora A","volume":"8","author":"Cazares-Korner","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0185","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-11-2296","article-title":"The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia","volume":"18","author":"Wang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0190","first-page":"62","article-title":"Hypoxia-activated prodrugs and (lack of) clinical progress: the need for hypoxia-based biomarker patient selection in phase III clinical trials","volume":"15","author":"Spiegelberg","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0195","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1158\/1535-7163.MCT-07-0428","article-title":"Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells","volume":"7","author":"Takata","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0200","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00066-012-0085-4","article-title":"Acute versus chronic hypoxia in tumors: controversial data concerning time frames and biological consequences","volume":"188","author":"Bayer","year":"2012","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0205","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tibtech.2014.09.006","article-title":"Methods to study the tumor microenvironment under controlled oxygen conditions","volume":"32","author":"Byrne","year":"2014","journal-title":"Trends Biotechnol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2021.04.030_bb0210","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.33549\/physiolres.931923","article-title":"Hypercapnia attenuates hypoxic pulmonary hypertension by inhibiting lung radical injury","volume":"58","author":"Chovanec","year":"2009","journal-title":"Physiol. Res."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0215","series-title":"Applied Biopharmaceutics & Pharmacokinetics","author":"Shargel","year":"2007"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0220","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1074\/jbc.M508847200","article-title":"The structure of dimeric ROCK I reveals the mechanism for ligand selectivity","volume":"281","author":"Jacobs","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.apradiso.2009.11.002","article-title":"Radiosynthesis of N-[11C]-methyl-hydroxyfasudil as a new potential PET radiotracer for rho-kinases (ROCKs)","volume":"68","author":"Valdivia","year":"2010","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.apradiso.2009.11.002","article-title":"Radiosynthesis of N-[(11)C]-methyl-hydroxyfasudil as a new potential PET radiotracer for rho-kinases (ROCKs)","volume":"68","author":"Valdivia","year":"2010","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0235","series-title":"Prodrugs of 1-(1-Hydroxy-5-isoquinolinesulfonyl) Homopiperazine","author":"Imadul Islam","year":"2004"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0240","series-title":"New Isoquinoline Derivative and Medicine Containing the Same","author":"Hiroyoshi Hidaka","year":"2006"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1039\/b109776h","article-title":"N- and O-alkylation of isoquinolin-1-ones in the Mitsunobu reaction: Development of potential drug delivery systems","author":"Ferrer","year":"2002","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0250","doi-asserted-by":"crossref","first-page":"13756","DOI":"10.1021\/acs.joc.7b02775","article-title":"Photoreductive removal of O-benzyl groups from oxyarene N-heterocycles assisted by O-pyridine\u2013pyridone Tautomerism","volume":"82","author":"Todorov","year":"2017","journal-title":"J. Organ. Chem."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0255","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0360-3016(98)00308-3","article-title":"Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug","volume":"42","author":"Raleigh","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0260","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bcp.2007.06.014","article-title":"Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia","volume":"74","author":"Guise","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1253\/circj.70.174","article-title":"Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension","volume":"70","author":"Ishikura","year":"2006","journal-title":"Circ. J."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1021\/acschembio.0c00890","article-title":"Discovery of 4,4\u2032-dipyridylsulfide analogs as \u201cswitchable electrophiles\u201d for covalent inhibition","author":"Ahn","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.brainres.2007.12.002","article-title":"Effects of acute hypoxia on intracellular-pH regulation in astrocytes cultured from rat hippocampus","volume":"1193","author":"Bevensee","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0280","first-page":"1341","article-title":"Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of endstage pulmonary hypertension with left heart disease","volume":"42","author":"Zhuang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0285","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrurol.2014.278","article-title":"Understanding and targeting the Rho kinase pathway in erectile dysfunction","volume":"11","author":"Sopko","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0290","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0295","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(17)30401-1","article-title":"Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation","volume":"18","author":"Lindner","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0300","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/cb4001537","article-title":"CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia\/reoxygenation through inhibition of Chk1 and Aurora A","volume":"8","author":"Cazares-Korner","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00280-010-1354-5","article-title":"Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice","volume":"67","author":"Gu","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0310","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2014-12-618900","article-title":"AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia","volume":"126","author":"Moradi Manesh","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.04.030_bb0315","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1289\/ehp.8564309","article-title":"Some reactions and properties of nitro radical-anions important in biology and medicine","volume":"64","author":"Wardman","year":"1985","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0320","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/s41467-018-04607-9","article-title":"Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer","volume":"9","author":"Nam","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0325","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2021.04.030_bb0330","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ccr.2011.07.016","article-title":"Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL","volume":"20","author":"Mali","year":"2011","journal-title":"Cancer Cell"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921001966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921001966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:59:37Z","timestamp":1759161577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921001966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":66,"alternative-id":["S0168365921001966"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.04.030","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}